- MASTERPLAN MICROBIOME
If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.
Understanding the effect of chemotherapy on microbial composition of pancreatic ductal adenocarcinoma (PDAC) patients
Purpose of the Study
Pancreatic cancer is the fourth most common cause of cancer death in Australia and it is critical to develop a new treatment for patients with pancreatic cancer who have limited life expectancy. Increasing body of research suggest that bacteria within human body may be responsible for the development and survival of pancreas cancer. There is an emerging idea that changing gut bacteria may improve the effects of chemotherapy.
The MASTERPLAN Microbiome study is a translational research substudy within the MASTERPLAN trial to collect serial bacterial samples from patients receiving chemotherapy as part of MASTERPLAN trial. The main goal is to describe how the gut bacteria will change before and after chemotherapy.
DETAILED INFORMATION AVAILABLE
More detailed information to come.
Professor David Goldstein
2020 Innovation Grant
If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.